Physician profile
Tu Bui
NPI 1396894903
$18,728.73
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,365 · 2020: $2,679 · 2021: $4,215 · 2022: $7,110 · 2023: $2,424 · 2024: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,343 · Education: $16.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.06 |
| Education | $16.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $4,768.07 | 2020-2022 | |
| Abbvie INC. | $1,502.23 | 2020-2024 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,399.03 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Biohaven Pharmaceuticals, INC. | $1,343.88 | 2021 | |
| Novo Nordisk INC | $805.68 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $692.72 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $680.79 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $655.55 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $652.35 | 2019-2024 | |
| Allergan, INC. | $570.39 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $545.82 | 2019-2024 | Rexulti |
| Amgen INC. | $532.89 | 2019-2023 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $433.59 | 2019-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $409.56 | 2019-2023 | |
| Abbott Laboratories | $401.90 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tu Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.